ENTA — ENANTA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1177648 ·
Last close
$14.10
Market Cap
$410.67M
52W High
$15.51
52W Low
$10.86
ADV30
180,964
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 17,159,000 | — | -11,852,000 | -13,091,000 | 314,704,000 | 34,928,000 | 198,117,000 |
| Dec 2025 | 18,615,000 | — | -11,253,000 | -11,938,000 | 329,503,000 | 37,437,000 | 202,912,000 |
| Sep 2025 | 15,125,000 | — | -18,386,000 | -18,700,000 | 280,732,000 | 32,298,000 | 216,015,000 |
| Jun 2025 | 18,314,000 | — | -18,893,000 | -18,255,000 | 301,029,000 | 44,812,000 | 221,750,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,838,000
Investing CF
$-59,543,000
Financing CF
$42,096,000
CapEx
$-1,771,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.59
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-429,958,000
Inventory
—
Receivables
$7,828,000
ST Investments
$128,846,000
EBIT TTM
$-51,488,000
Pretax Income TTM
$-61,892,000
Interest Exp TTM
$10,404,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$65,258,000
EBITDA
$-53,819,000
Free Cash Flow
$-22,656,876
Enterprise Value
$384,853,152
Total Cash
$189,506,000
Total Debt
$182,040,000
Shares Out
29,125,402
Trailing EPS
$-2.42
Book Value
$3.47
ROE
-70.1%
ROA
-12.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 65,324,000 | -85,349,000 | -81,889,000 | 280,732,000 | 216,015,000 | — | -19,272,000 |
| Sep 2024 | 67,635,000 | -121,691,000 | -116,045,000 | 376,652,000 | 247,838,000 | — | -78,764,000 |
| Sep 2023 | 79,204,000 | -137,207,000 | -133,816,000 | 462,275,000 | 245,540,000 | — | -103,154,000 |
| Sep 2022 | 86,160,000 | -123,844,000 | -121,755,000 | 375,410,000 | 54,076,000 | — | -84,782,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.53
Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $14.10 · call volume: 134 · put volume: 3
Expected Move to 2026-09-18:
±$1.97
(14.01%) —
implied range
$12.13 –
$16.08
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| FHTX | Foghorn Therapeutics Inc. | $407.98M | $6.87 | — |
| ARCT | Arcturus Therapeutics Holdings Inc. | $407.59M | $14.34 | — |
| PRLD | Prelude Therapeutics Inc | $420.01M | $6.47 | — |
| LRMR | Larimar Therapeutics, Inc. | $420.73M | $4.05 | — |
| CAPR | CAPRICOR THERAPEUTICS, INC. | $395.35M | $6.80 | — |
News headlines (Yahoo Finance, 1h cache)
Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates
2026-08-10 21:10 · Yahoo
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
2026-08-10 20:01 · Yahoo
Enanta Pharmaceuticals (ENTA) Moves 5.2% Higher: Will This Strength Last?
2026-06-24 13:13 · Yahoo
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
2026-06-23 09:10 · Yahoo
Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)
2026-06-18 11:00 · Yahoo
Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?
2026-05-07 13:02 · Yahoo
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
2026-07-21 14:08 · Yahoo
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Lags Revenue Estimates
2026-05-11 21:10 · Yahoo
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates
2026-05-07 21:55 · Yahoo
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
2026-03-15 22:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.